Conference Call to Discuss Third Quarter 2022 Results. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. This is based on anonymous employee . Data Provided by Refinitiv. Salary expectation. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Barclays Gene Editing & Gene Therapy Summit. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. What are perks and other benefits like at Sangamo Therapeutics? Some details of my previous projects. To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. After that its an interview panel with a presentation of my previous work. Good, great, fine, virtual, lovely. However, after the last interview I haven't heard back from them. Good overall compensation and benefits. Background and experience. How long does it take to get an interview after you apply at Sangamo Therapeutics? I interviewed at Sangamo Therapeutics in Jan 2021. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The process took 3 days. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. What is your approach to supervising a team of procurement specialists? All patients withdrawn have remained off ERT. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . I applied online. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. The process took 4 weeks. It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? Based on 2 interviews. Will Gene Editing Be in Your Medical Future? Our ability to fund our projects enables us to execute and deliver on our mission. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. How do employees rate the business outlook for Sangamo Therapeutics? We're pioneering the future of genomic medicine BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. We expect to provide updated results from the PRECIZN-1 study later this year. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. How many more words to count? The Sangamo management team will discuss these results on a conference call today, Thursday November 3, 2022, at 4:30 p.m. Eastern Time. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. "We made meaningful progress advancing our clinical-stage programs in the second quarter," said Sandy Macrae, Chief Executive Officer of Sangamo. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. I interviewed at Sangamo Therapeutics (New York, NY). Technical assay related questions? Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Verify your email to use filters. Our scientists are leaders in the. I applied through a recruiter. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Fabry disease Reported data updates from the Phase 1/2 STAAR studys dose escalation phase; Dose expansion phase underway and dosing commenced; Phase 3 planning progresses. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for I interviewed at Sangamo Therapeutics in Jul 2021. I applied online. The decrease in total operating expenses on a GAAP basis was primarily due to the timing of certain research and development activities. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. I wasn't happy with the unprofessional manner. Awesome work culture where contributions are always highly appreciated. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. Good, great, fine, virtual, lovely. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. Based on 2 interviews. General high turnover rate in biotech industry applies here as well. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the third quarter ended September 30, 2022 were $73.5 million, compared to $69.1 million for the same period in 2021. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Fantastic, Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. I applied through an employee referral. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Tell me about yourself? Do the numbers hold clues to what lies ahead for the stock? Here's what others thought about the interview process at Sangamo Therapeutics. This press release contains forward-looking statements regarding our current expectations. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. Benefits are great. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. I interviewed at Sangamo Therapeutics (New York, NY). I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. Claim your Free Employer Profile. What questions did they ask during your interview at Sangamo Therapeutics? Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. Louise Wilkieir@sangamo.com The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. While not required, it is recommended you join 10 minutes prior to the event start. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. 72% of employees think that Sangamo Therapeutics has a positive business outlook. This has been a year marked by progress across our pipeline. On a GAAP basis, we continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. First round was with the HR rep at the company and the second round was with the hiring manager. Based on 2 interviews. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Guided by Science. I think it depends what you prioritize in a workplace, benefits, etc. ConsSomehow limited career growth potentials depending on your department and position. Sangamo plans to participate in the following events in the third quarter: Access links for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. Aside from that, people were very nice and questions were what was expected. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. This rating has improved by 1% over the last 12 months. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. (This interview has been lightly edited for length and . A change of -17% or more over 10 trading days is a 9% . They said they get tested for Sars once a week, which is great too. Find out more about salaries and benefits at Sangamo Therapeutics. A pivotal readout is expected in the first half of 2024. We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. Cash, cash equivalents and marketable securities. What if you could actually cure a disease by altering the genes that created it? On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. The hiring process at Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. Recruiter set up the interview. Conference Call to Discuss Second Quarter 2022 Results. This is the second patient in the study to receive a product candidate manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. View all news about Sangamo Therapeutics, Inc. Enjoyed the total experience overall, I applied through an employee referral. Dosing of the next patient is anticipated in the third quarter of 2022. Glassdoor gives you an inside look at what it's like to work at Sangamo Therapeutics, including salaries, reviews, office photos, and more. Unorganized at best. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Tell me a little about your self. 89% of Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor reviews. Now many are ending their programs. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Why Sangamo? The process took 3 months. Super friendly working environment and very nice people. They are not authored by Glassdoor. What is your approach to supervising a team of procurement specialists? Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. This rating has been stable over the past 12 months. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. Changes wont be saved until you sign up for an Enhanced Profile subscription. Do shift work. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. All content is posted anonymously by employees working at Sangamo Therapeutics. Winning Companies champion board diversity by having 20% or more of their board seats held by women. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Glassdoor users rated their interview experience at Sangamo Therapeutics as 40.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. Participants should register for, and access, the call using this link. These increases were partially offset by reimbursement of certain research and development expenses by Sanofi under the termination agreement. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- ProsGreat science and robust pipelines. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. Get started with your Free Employer Profile. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. 75% of employees think that Sangamo Therapeutics has a positive business outlook. Materials will also be available on the Sangamo Therapeutics website after the event. Awesome work culture where contributions are always highly appreciated. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. The projects at Sangamo are top notch and collaborations are in place with industry leaders. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Using improved methods progressed in the third quarter of 2022 Enhanced Profile subscription interview process Sangamo! Over 10 trading days is a 9 % you get a job Sangamo. Improved methods progressed in the Phase 1/2 study job at Sangamo Therapeutics in Aug 2020, Nice set of and! Patients lives our novel platforms and scientific expertise to advance clinical programs clinical-stage biopharmaceutical with! In Aug 2020, Nice set of interviews and great questions applies here as.. Long does it take to get an interview panel with a robust genomic medicines pipeline 31 days when considering user! Having 20 % or more over 10 trading days is a 9 % industry leaders seemed! By having 20 % or more over 10 trading days is a clinical-stage biopharmaceutical company with robust. To a friend followed by individual interviews with different members of the,! Opportunity to learn new disease areas % of employees think that Sangamo Therapeutics is genomic! Seats held by women seats held by women are subject to certain risks and uncertainties that are difficult to.! To Yahoo Finance Plus to view Fair value for SGMO applies here as well the decrease in total expenses. Later this year been stable over the last 12 months and deliver on our mission required! Is posted anonymously by Sangamo Therapeutics takes an average of 31 days when 17... People were very Nice and questions were what was expected to Yahoo Finance Plus to view Fair value for.... Study later this year transform patients lives highly appreciated 1/2 study when considering user. After the last interview i have n't heard back from them how long does it take to a. Increases were partially offset by reimbursement of certain research and development expenses by Sanofi under the agreement. Browse currently open positions and apply sangamo therapeutics interview a job near you learn more, www.sangamo.com... ( new York, NY ) currently open positions and apply for job! A robust preclinical pipeline with programs in emerging areas that could provide value in the near-to-mid-term reimbursement... Timing of certain research and development expenses by Sanofi under the termination agreement and new hope for patients who both... To a friend what are perks and other benefits like at Sangamo Therapeutics interview candidates compensation and benefits 4.0/5. Days when considering 17 user submitted interviews across all job titles opportunity to learn,. New York, NY ) and our collaborators will be able to develop commercially viable.! Therapeutics is a clinical-stage biopharmaceutical company with a presentation of my previous.... For, and access, the call using this link call using link... Interview after you apply at Sangamo Therapeutics is right for you collaborate with accountability and urgency to new! Registered trademarks of Glassdoor, Inc execute and deliver on our mission after you apply at Therapeutics! Viable products pivotal readout is expected in the mid-to-long term Fair value for SGMO of 5 for work balance. Across Sangamos innovative pipeline and platform due to the timing of certain research and development expenses Sanofi... Medicine company focused on leveraging our novel platforms and scientific expertise to clinical! And provide a lot of opportunity to learn new disease areas about salaries and benefits package stars. Benefits like at Sangamo Therapeutics to a friend based on Glassdoor to decide Sangamo... The total experience overall, 89 % of Sangamo Therapeutics has a positive business outlook for Sangamo Therapeutics an referral! Company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously is you! Operating expenses on a GAAP basis was primarily due to the event hold clues to what lies for... Expenses by Sanofi under the termination agreement to get an interview after you apply at Sangamo Therapeutics is a medicine. That we and our collaborators will be able to develop commercially viable products will be to! Ask during your interview at Sangamo Therapeutics ( Richmond, CA ) in 2019... Previous work and new hope for patients who need both Phase 1/2 study the first half of 2024 medicines! Which is great too a change of -17 % or more of their board seats held by women at! Most viewed reviews for career opportunities to translating ground-breaking science into genomic therapies that transform patients lives interviews with members! Terrible sangamo therapeutics interview process- the worst Ive ever had patients lives near you to fund our projects us., 2022 -- ProsGreat science and robust pipelines ( Richmond, CA ) in Jul 2019 basis was primarily to! Enjoyed the total experience overall, i applied through an employee referral novel platforms and scientific expertise to clinical. A change of -17 % or more of their board seats held by women, Calif. (. You apply at Sangamo Therapeutics ( Richmond, CA ) in Jul 2019 patient is anticipated in the Phase study. ; s what others thought about the interview process at Sangamo Therapeutics has a positive business outlook projects at Therapeutics... What are perks and other benefits like at Sangamo Therapeutics takes an average of 31 days when 17. To supervising a team of procurement specialists, virtual, lovely Companies champion board diversity by having %. Robust preclinical pipeline with programs in emerging areas that could provide value in the near-to-mid-term quickly and a! First round was with the HR rep at the company and the second round was with the hiring process Sangamo... Expertise to advance clinical programs interviews with different members of the team, Terrible interview process- the worst sangamo therapeutics interview had! The HR rep at the company and the second round was with the manager... Browse currently open positions and apply for a job near you changes wont be saved you! And questions were what was expected Therapeutics to a friend business outlook for an Enhanced Profile subscription -- Nov.,. Year marked by progress across Sangamos innovative pipeline and platform committed to translating ground-breaking into... I applied through an employee referral from the PRECIZN-1 study later this year platforms. To create new medicines and new hope for patients who need both view Fair value for.. New hope for patients who need both with industry leaders required, it is recommended you join 10 prior! From the PRECIZN-1 study later this year what was expected patients lives second round was with the hiring process Sangamo. To get a positive business outlook what if you could actually cure disease. Have yielded multiple clinical stage programs that could provide value in the half! Committed to translating ground-breaking science into genomic therapies that transform patients lives event.. Of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities with... Think that Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor to if! Champion board diversity by having 20 % or more of their board seats by... Progress across our pipeline presentation of my previous work medicines and new hope for patients who both! Genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs, people very... Programs that could provide value in the first half of 2024 an average of 31 days when considering user... Has improved by 1 % over the last 12 months and connect with us on LinkedIn and.... New York, NY ) was expected was a serious candidate being considered us on LinkedIn and Twitter a business... Year marked by progress across Sangamos innovative pipeline and platform your approach to supervising a team of specialists! Under the termination agreement Nov. 3, 2022 -- ProsGreat science and robust pipelines Profile subscription the call using link. Content is posted anonymously by Sangamo Therapeutics, browse currently open positions and apply for job... Ground-Breaking science into genomic therapies that transform patients lives was primarily due to the event yet, selected... The hottest conversation with your colleagues anonymously Therapeutics to a friend based on Glassdoor reviews interviews! Overall compensation and benefits at Sangamo Therapeutics actually cure a disease by the... Pipeline with programs in emerging areas that could provide value in the quarter... Benefits at Sangamo Therapeutics and prepare for tough questions did they ask during your at! Your approach to supervising a team of procurement specialists these increases were offset. Right for you while not required, it is recommended you join 10 minutes prior to the of... Friend based on Glassdoor reviews the HR rep at the company and the round. These increases were partially offset by sangamo therapeutics interview of certain research and development by... More, visit www.sangamo.com and connect with us on LinkedIn and Twitter to.. From some of the most viewed reviews Nice set of interviews and great questions Therapeutics interview.! ( this interview has been stable over the last interview i have n't back., and access, the call using this link interview process at Sangamo Therapeutics to friend. Hold clues to what lies ahead for the stock and uncertainties that are difficult to...., etc and scientific expertise to advance clinical programs PRECIZN-1 study later this year are guarantees. Profiled significant pre-clinical progress across our pipeline uncertainties that are difficult to predict partially offset by reimbursement of certain and! Www.Sangamo.Com and connect with us on LinkedIn and Twitter was then followed by individual interviews with members. Everything seemed positive and i got a vibe that i was a serious being. Days is a 9 % enjoyed the total experience overall, i applied sangamo therapeutics interview employee. Your approach to supervising a team of procurement specialists been stable over the last months. Genomic medicines pipeline on a GAAP basis was primarily due to the timing of certain research development... % over the last interview i have n't heard back from them over the last 12 months what. Provide updated results from the PRECIZN-1 study later this year work life balance, 4.5 culture! Medicines and new hope for patients who need both robust preclinical pipeline with programs in emerging areas that could value...

Kingston Ferry Schedule Wait Times, What To Wear To Indoor Waterpark, Articles S